Financials

We are an innovative medical technology company primarily focused on improving women’s health and well-being through early detection and treatment.

Download item year list
Date Download Description

We enable healthier lives, everywhere, every day As the leader women’s health, we deliver life-changing and life-saving diagnostic, detection, surgical and medical aesthetic products that are rooted in science, driven by technology, and inspired by our desire to empower women and help healthcare professionals diagnose and treat their patients with growing certainty, precision, and ever-greater peace of mind.

Genius 3D exam
Genius™ 3D™ exam

The Genius™ 3D Mammography™ exam detects 20-65% more breast cancers compared to 2D mammography alone.2

Affirm Prone Biopsy System
Affirm® Prone Biopsy System

TheSuperior biopsy imaging using Genius 3D technology. Vastly improved workflow results in faster procedures and an enhanced patient experience.

Horizon DXA Bone Densitometry
Horizon™ DXA Bone Densitometry

Provides high-quality clinical images that reveal the smallest fractures at the earliest stage — helping to keep patients strong and healthy. Horizon™ was designed to assess osteoporosis, obesity and aortic calcifications.

NovaSure for AUB
NovaSure® for AUB

NovaSure endometrial ablation for abnormal uterine bleeding (AUB) can dramatically improve a woman’s comfort, confidence and quality of life. It is a safe, simple solution used by more than 2 million women since 2001.

MyoSure Hysteroscopic Tissue Removal
MyoSure® Hysteroscopic Tissue Removal

The MyoSure procedure enables fast, safe removal of fibroids, polyps and retained products of conception in less than 15 minutes — without having to make a single incision. It enables convenient removal of intrauterine pathology under direct visualization.

SculpSure
SculpSure®

SculpSure® is the first FDA-cleared, light-based device for non-surgical fat reduction. The procedure permanently eliminates fat cells in problem areas. Each treatment takes about 25 minutes and patients work with their physicians to develop a customized treatment plan

Panther System
Panther® System

Offers best-in-class automation and workflow for molecular diagnostics, giving laboratories greater freedom and flexibility with true walkaway processing and random access sampling. Delivers a broad menu of the most sensitive, accurate, and precise assays.

Aptima Molecular Diagnostic Assays
Aptima® Molecular Diagnostic Assays

Hologic developed the first FDA-cleared nucleic acid test for infectious diseases over 30 years ago. Today, our state-of-the-art Aptima assays quickly identify diseases like chlamydia, gonorrhea, HPV & trichomoniasis at early stages, often within days of infection.

ThinPrep Pap test
ThinPrep® Pap test

Cervical cancer was the #1 cancer killer of women prior to the introduction of Pap screening, now it’s #14.3 Hologic’s ThinPrep liquid-based cytology test has revolutionized cervical cancer screening and is the leading cervical specimen collection product in the world.

Brevera Breast Biopsy System
Brevera® Breast Biopsy System

The Brevera® breast biopsy system with CorLumina® imaging technology is the world’s first and only solution to combine tissue acquisition, real-time imaging, verification and advanced post-biopsy handling—all in one, integrated system.

TempSure Envi
TempSure™ Envi

TempSure™ Envi is a radiofrequency treatment that safely delivers consistent and reliable skin tightening4 and tissue heating through its unique time and temperature control capability.

1. The Genius™ exam is only available on the Hologic® 3D Mammography™ system. Please visit www.MyGenius3D.com/pro for more information. 2. Friedewald SM, Rafferty EA, Rose SL, et al. Breast cancer screening using tomosynthesis in combination with digital mammography. JAMA. 2014 Jun 25;311(24):2499-507. 3. https://www.report.nih.gov/nihfactsheets/viewfactsheet.aspx?csid=76 4. Through soft tissue coagulation.

Financial Fast Facts

Revenue Highlights 4Q18

Revenue Highlights 3Q18

Financial Overview 4Q18

Financial Overview 3Q18

Net Debt & Leverage Ratio3

Net Debt & Leverage Ratio

Capital Deployment Priorities

Expect free cash flow OF APpROXIMATELY $700
million in FY19*

Business development

  • Blood divestiture, Cynosure acquisition shifted portfolio toward higher growth segments
  • Tuck-in acquisitions
  • Accretive to revenue, EPS growth rates
  • Attractive ROIC
  • Leveraging existing sales channels

share repurchases

  • $411.5 million remaining on board authorization

Revenue4

Revenue

4Q18 YTD Divisional Revenue by Geography

3Q18 YTD Divisional Revenue by Geography

Non-GAAP EPS4

Non-GAAP EPS

% Operating Margin

% Operating Margin

ROIC5

ROIC
Financial-Guidance

*Excluding one-time items such as acquisition-related tax payments and legal settlements.

1. Includes contributions from divested blood screening business. Excluding blood, Diagnostics sales increased 0.8% on a reported basis, or 1.4% in constant currency.
2. Guidance provided by press release on 11/7/18. Presentation here is not, and should not be construed as, re-affirmation of guidance. Guidance assumes diluted shares outstanding of approximately 276 million for the full year and an annual effective tax rate of approximately 23%.
3. Net debt is total debt minus cash; leverage ratio is principal debt minus cash to TTM adjusted EBITDA.
4. Total non-GAAP revenue and EPS growth as reported with the exception of FY14, which excludes ~$20 million one-time revenue contribution from restructuring of Roka license, which increased operating margin and added $0.05 to EPS. Reconciliations to GAAP are available in quarterly financial releases and at Hologic.com/investors.
5. ROIC on a Trailing Twelve Month basis, defined as adjusted net operating profit after tax divided by average net debt plus stockholders’ equity.

Quicklinks